Monotherapy with long-acting TRAIL eradicates large tumor grafts of CRC cells with chemotherapeutic MDR, but not CRC cells with both chemotherapeutic MDR and TRAIL resistance. Here, TNFSF10 is linked to colorectal carcinoma.